Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Lack of prognostic value of epidermal growth factor receptor in a series of 229 T1/T2, N0/N1 breast cancers, with well defined prognostic parameters

  • 17 Accesses

  • 5 Citations

Summary

The prognostic value of epidermal growth factor receptor (EGF-R) was prospectively assessed in a series of 229 clinical T1-T2, N0-N1 breast carcinomas diagnosed between May 1987 and October 1989. EGF-R expression was determined by measuring the specific Bmax of125I EGF to tumor plasma membrane preparations. Tumor with a B max ≥ 3 fmol/mg of protein were considered positive with regard to EGF-R expression. With a median follow-up of 34 months, the 3-year overall and disease-free survivals are respectively 92% and 88% for EGF-R ≤ 3, and 91% and 86% EGF-R > 3 fmol, showing no significant difference, even when comparing axillary lymph node status. We did not succeed in finding an EGF-R cut-off value which might be significant in univariate analysis. Multivariate analysis of our data indicates that pT (p = 0.001), pN (p = 0.04), and Scarff-Bloom grade (p = 0.04) are the only significant predictors of disease-free survival among the parameters investigated in this study.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Benraad TJ, Foekens JA: Hydroxylapatite assay to measure epidermal growth factor receptor in human primary breast tumors. Ann Clin Biochem 27: 272–273, 1990

  2. 2.

    Bolla M, Chedin M, Souvignet C, Marron J, Arnould C, Chambaz EM: Estimation of epidermal growth factor receptor in 177 breast cancers. Correlation with prognostic factors. Breast Cancer Res Treat 16: 97–102, 1990

  3. 3.

    Bolla M, Chedin M, Colonna M, Marron J, Rostaing-Puissant B, Chambaz EM: Prognostic value of epidermal growth factor receptor in a series of 303 breast cancers. Eur J Cancer 28A: 1052–1054, 1992

  4. 4.

    Falette N, Lefebvre ML, Meggouh F, Eynard M, Garin E, Saez S: Measurement of epidermal growth factor occupied and non occupied receptor sites in 216 human breast cancer biopsies. Breast Cancer Res Treat 20: 177–183, 1991

  5. 5.

    Fitzpatrick SL, Brightwell J, Wittliff JL, Barrows GH, Schultz GS: Epidermal growth factor binding by breast tumor biopsies and relationship to oestrogen receptor and progestin receptor levels. Cancer Res 44: 3448–3453, 1984

  6. 6.

    Foekens JA, Portengen H, Van Putten WLJ, Trapman A, Reubi JC, Alexieva-Figusch J, Klijn JGM: Prognostic value of receptors for insuline-like growth factor 1, somatostatin and epidermal growth factor in human breast cancer. Cancer Res 49: 7002–7009, 1989

  7. 7.

    Formento JL, Francoual M, Formento P, Etienne MC, Fischel JL, Namer M, Frenay M, François E, Milano G: Epidermal growth factor receptor assay: validation of a single point method and application to breast cancer. Breast Cancer Treat Res 17: 211–219, 1990

  8. 8.

    Gasparini G, Bevilacqua P, Pozza F, Meli S, Boracchi P, Marubini E, Sainsbury JRC: Value of epidermal growth factor receptor status compared with growth fraction and other factors for prognosis in early breast cancer. Br J Cancer 66: 970–976, 1992

  9. 9.

    Grimaux M, Romain S, Remvikos Y, Martin PM, Magdelenat H: Prognostic value of epidermal growth factor receptor in node positive breast cancer. Breast Cancer Res Treat 14: 77–90, 1989

  10. 10.

    Koenders PG, Beex LVAM, Geurts-Moespot A, Heuvel JJTM, Kienhuis CBM, Benraad TJ: Epidermal growth factor receptor-negative tumors are predominantly confined to the subgroup of estradiol receptor positive human primary breast cancers. Cancer Res 51: 4544–4548, 1991

  11. 11.

    Koenders P, Beex LVAM, Kienhuis C, Kloppenborg P, Benraad T: Epidermal growth factor receptor and prognosis in human breast cancer: a prospective study. Breast Cancer Res Treat 23: abstract 16, 134, 1992

  12. 12.

    Nicholson S, Sainsbury JRC, Halcrow P, Kelly P, Angus B, Wright C, Henry Y, Farndon JR, Harris AL: Epidermal growth factor receptor: results of a six year follow-up study in operable breast cancer with emphasis on the node negative subgroup. Br J Cancer 63: 146–151, 1991

  13. 13.

    Osborne CK: Prognostic factors for breast cancer: have they met their promise? J Clin Oncol 10: 679–682, 1992

  14. 14.

    Rostaing-Puissant B, Chedin M, Chambaz EM, Bolla M: Activité protéine (Tyrosine)-kinases dans les tumeurs du sein. Relation avec les divers paramètres de pronostic. Bull Cancer 78: 482–483, 1991

  15. 15.

    Sainsbury JRC, Farndon JR, Sherbet GV, Harris AL: Epidermal growth factor receptors and estrogen receptors in human breast cancer. Lancet i: 364–366, 1985

  16. 16.

    Sainsbury JRC, Farndon JR, Needham GK, Malcom AJ, Harris AL: Epidermal growth factor receptor status as predictor of early recurrence and death from breast cancer. Lancet i: 1398–1402, 1987

  17. 17.

    Sokal R, Rohlt F (eds): Biometry. Freeman, New York, 1981

  18. 18.

    Spyratos F, Delarue JC, Andrieu C, Lidereau R, Champene MH, Hacène K, Brunet M: Epidermal growth factor receptors and prognosis in primary breast cancer. Breast Cancer Res Treat 17: 83–90, 1990

  19. 19.

    Toi M, Osaki A, Yamada H, Toge T: Epidermal growth factor receptor expression as a prognostic indicator in breast cancer. Eur J Cancer 27: 977–980, 1991

Download references

Author information

Correspondence to M. Bolla.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Bolla, M., Chedin, M., Colonna, M. et al. Lack of prognostic value of epidermal growth factor receptor in a series of 229 T1/T2, N0/N1 breast cancers, with well defined prognostic parameters. Breast Cancer Res Tr 29, 265–270 (1994). https://doi.org/10.1007/BF00666480

Download citation

Key words

  • epidermal growth factor receptor
  • breast cancer
  • prognostic factor